| Code | CSB-RA023981MB10HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to INCAGN-1949, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a costimulatory receptor expressed primarily on activated T cells that plays a crucial role in T cell proliferation, survival, and effector function. Upon binding to its ligand OX40L, this receptor enhances T cell-mediated immune responses and promotes the generation of memory T cells. TNFRSF4 has emerged as an important immunotherapeutic target in oncology, as its activation can enhance anti-tumor immunity by promoting effector T cell responses while potentially modulating regulatory T cell function within the tumor microenvironment.
INCAGN-1949 is an investigational agonistic antibody designed to stimulate OX40 signaling and enhance anti-tumor immune responses. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF4 biology, T cell activation mechanisms, and immune checkpoint modulation in various cancer models. It enables researchers to explore combination immunotherapy strategies and elucidate the role of OX40 signaling in tumor immunity and autoimmune conditions.
There are currently no reviews for this product.